The effects of orlistat on metabolic parameters and other cardiovascular risk factors
Diabetes & MetabolismPublished 1 February 2005
DN Kiortsis, Theodosios D. Filippatos, Moses Elisaf
Citations66
SJR quartileQ1
SJR score1.65
SNIP1.16
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance and appears to have a favourable effect on some inflammatory markers, such as TNF-alpha and interleukin-6 and has a time-depended effect onSome haemostatic factors.
Abstract
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in serum insulin levels. Moreover, orlistat reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance and lowers the required dose of metformin, sulfonylureas and insulin in patients with type 2 diabetes. Furthermore, orlistat can reduce total and low density lipoprotein (LDL) cholesterol levels and improve postprandial triglyceridemia, as well as the low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). Moreover, orlistat appears to have a favourable effect on some inflammatory markers, such as TNF-alpha and interleukin-6 and has a time-depended effect on some haemostatic factors.
Keywords
Medicine
Trends in ImmunologyInflammation: the link between insulin resistance, obesity and diabetes
2,147 Citations2003P Dandona
The increased concentrations of TNF-alpha and IL-6, associated with obesity and type 2 diabetes, might interfere with insulin action by suppressing insulin signal transduction, which might interfering with the anti-inflammatory effect of insulin, which in turn might promote inflammation.
Diabetes CareXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
1,902 Citations2004Jarl Torgerson, Jonathan Hauptman +2 more
Compared with lifestyle changes alone, orlistat plus lifestyle changes resulted in a greater reduction in the incidence of type 2 diabetes over 4 years and produced greater weight loss in a clinically representative obese population.
The LancetRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
1,203 Citations1998Lars Sjöström, Aila Rissanen +5 more
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period and the use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
JAMAWeight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat
937 Citations1999Michael Davidson, Jonathan Hauptman +9 more
Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.
Diabetes CareRole of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
657 Citations1998Priscilla Hollander, Steven C. Elbein +13 more
Orlistat is an effective treatment modality in obese patients with type 2 diabetes with respect to clinically meaningful weight loss and maintenance of weight loss, improved glycemic control, and improved lipid profile.
The American Journal of CardiologyThe metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
531 Citations2004Cynthia J. Girman, Thomas Rhodes +7 more
It is demonstrated that the metabolic syndrome is associated with increased risk of MCEs in both hypercholesterolemic patients with coronary heart disease in 4S and in those with low high-density lipoprotein cholesterol but without coronaryHeart disease in AFCAPS/TexCAPS.
Obesity ResearchWeight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity
479 Citations2000Stephan Rössner, Lars Sjöström +4 more
Orlistat administered for 2 years promotes weight loss and minimizes weight regain, and additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life.
Archives of Family MedicineOrlistat in the Long-term Treatment of Obesity in Primary Care Settings
370 Citations2000Jonathan Hauptman
This long-term study indicates that orlistat is an effective adjunct to dietary intervention in the treatment of obesity in primary care settings and was well tolerated, although treatment resulted in a higher incidence of gastrointestinal events.
Obesity ReviewsObesity, haemostasis and the fibrinolytic system
363 Citations2002Ilse Mertens, Luc F. Van Gaal
The increased cardiovascular risk observed in obesity could in part be explained by the association between insulin resistance and components of the fibrinolytic and haemostatic systems.
Archives of Internal MedicineEffects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults
358 Citations2000Steven B. Heymsfield, Karen R. Segal +6 more
The addition of orlistat to a conventional weight loss regimen significantly improved oral glucoseolerance and diminished the rate of progression to the development of impaired glucose tolerance and type 2 diabetes.
Obesity ResearchRaised Interleukin‐6 Levels in Obese Patients
347 Citations2000Leonid Roytblat, Maxim Rachinsky +5 more
It is concluded that serum IL- 6 is increased in obese patients, and the highest IL-6 levels were found in the patients with OHS.
PubMedMode of action of orlistat.
327 Citations1997Roberto Guerciolini
Orlistat, a semisynthetic derivative of lipstatin, is a potent and selective inhibitor of gastric and pancreatic lipases, with little or no activity against amylase, trypsin, chymotrypsin and phospholipases.
Diabetes CareClinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes
312 Citations2002David E. Kelley, George A. Bray +5 more
Orlistat therapy produces clinically significant weight loss, with improvements in glycemic control and cardiovascular disease risk factors, in overweight or obese patients with type 2 diabetes who have suboptimal metabolic control with insulin therapy.
European Heart JournalThe Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm
297 Citations2004Jobien K. Olijhoek
In patients with manifest vascular disease the presence of the metabolic syndrome is associated with advanced vascular damage.
European Journal of PharmacologyOrlistat: its current status as an anti-obesity drug
295 Citations2002Anne Ballinger, Steven Peikin
Over a 1-year period, obese patients taking orlistat in combination with a hypocaloric diet show a reduction of 2-5 kg over the weight decrease with placebo, and when continued for a second year in conjunction with a weight maintenance diet, orlistats reduces weight regain compared to placebo-treated patients.
American Journal of Clinical NutritionOrlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study
290 Citations1999James O. Hill, Jonathan Hauptman +6 more
The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Diabetes CareEffect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin
285 Citations2002John M. Miles, Lawrence A. Leiter +7 more
Orlistat is a useful adjunctive treatment for producing weight loss and improving glycemic control, serum lipid levels, and blood pressure in obese patients with type 2 diabetes who are being treated with metformin.
Journal of Internal MedicineThe effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
205 Citations2000Folke Lindgärde
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients in the Swedish Multimorbidity Study is illustrated.
The Journal of Clinical PharmacologyReview of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers
172 Citations1995Jianguo Zhi, Angela T. Melia +3 more
The results of these studies indicate an extremely low degree of systemic absorption for orlistat when administered with a hypocaloric, well‐balanced diet with 20% to 30% of calories derived from fat (50–80 gm).
American Journal of Physiology-Gastrointestinal and Liver PhysiologyInhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers
170 Citations2001Frédéric Carrière, Christophe Renou +12 more
The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans and found to be a powerful gastric lipase inhibitor, greatly reducing gastriclipolysis of solid and liquid meals.
International Journal of ObesityThe effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study
166 Citations2001L Van Gaal for the ObelHyx Study Group, Erik Muls +3 more
Orlistat as an adjunct to dietary intervention promotes weight loss and reduces LDL-C beyond the effect of weight loss in overweight or obese patients with concomitant hypercholesterolemia and was generally well tolerated with a safety profile comparable to placebo.
Diabetes Obesity and MetabolismEvaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
165 Citations2002A. Gokcel, Yüksel Gümürdülü +5 more
A randomized, prospective clinical trial is designed to study the efficacy and safety of 10“mg sibutramine twice daily, and compare this treatment with 120 mg orlistat three times daily (tid) and 850‰mg metformin (bid).
Diabetes Obesity and MetabolismThe effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial
148 Citations2002M Hanefeld, G. Sachse
The aim of this study is to assess the long‐term effects of orlistat on body weight, glycaemic control and cardiovascular risk factors in overweight patients with type 2 diabetes.
Current Diabetes ReportsCardiovascular risk associated with the metabolic syndrome
120 Citations2004Robert S. Lindsay, Barbara V. Howard
The remarkable recent secular increases in the prevalence of type 2 diabetes and obesity in many populations mean that the importance of the metabolic syndrome as a determinant of cardiovascular disease is likely to increase until these trends can be reversed.
Obesity ResearchOrlistat Inhibits Dietary Cholesterol Absorption
114 Citations2001Bettina Mittendorfer, Richard E. Ostlund +2 more
Data demonstrate that orlistat inhibits dietary cholesterol absorption, which may have beneficial effects on lipoprotein metabolism in obese subjects that are independent of weight loss itself.
The American Journal of CardiologyEffect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X
111 Citations2001Gerald M. Reaven, Karen R. Segal +3 more
In conclusion, weight loss attenuates coronary heart disease risk factors in obese persons with syndrome X, and the risk factor reduction is enhanced with administration of orlistat.
International Journal of Clinical PracticeRANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY
102 Citations2002J. Broom, John Wilding +3 more
Orlistat weight loss is associated with improvements in cardiovascular co‐morbidities, and hence cardiovascular risk, and therefore cardiovascular risk in obese patients with cardiovascular risk.
Journal of HypertensionOrlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
95 Citations2002George L. Bakris, David A. Calhoun +4 more
A weight-loss program with orlistat is more effective than diet alone to lower blood pressure and results in greater cardiovascular risk reduction.
European Journal of Clinical PharmacologyThe effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia
93 Citations1994Serena Tonstad, D Pometta +9 more
Orlistat is a new therapeutic drug for the treatment of hyperlipidaemia that may be particularly useful among overweight patients and its potential place in therapy will await long-term studies.
Diabetes Obesity and MetabolismLatin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients
72 Citations2003Alfredo Halpern, Márcio C. Mancini +9 more
If obese non‐insulin‐dependent diabetic patients lose more weight when treated for 24’weeks with orlistat (120’mg t.i.d.), in conjunction with a hypocaloric diet plus behavioural counselling, than when treated by placebo plus similar instructions is determined.
Archives of Internal MedicineThe Effect of Orlistat-Induced Weight Loss, Without Concomitant Hypocaloric Diet, on Cardiovascular Risk Factors and Insulin Sensitivity in Young Obese Chinese Subjects With or Without Type 2 Diabetes
72 Citations2002Peter C.Y. Tong, Zoe S.K. Lee +10 more
Short-term orlistat treatment without the use of a hypocaloric diet significantly improved insulin sensitivity and cardiovascular risk profiles in severely obese Chinese patients with or without type 2 diabetes mellitus.
Clinical TherapeuticsRandomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet
71 Citations2003Giuseppe Derosa, Amedeo Mugellini +2 more
Improvements in clinical and lipid-profile parameters were found at 1 year and 1 year of treatment, and HDL-C was significantly higher than baseline in the F and OF groups (P < 0.02 and P <0.01, respectively).
MetabolismRelationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor
58 Citations1994Johannes B. Reitsma, M. Castro Cabezas +2 more
The present data indicated that pancreatic lipase inhibition improved postprandial lipoprotein metabolism, which in turn resulted in lower plasma total and LDL cholesterol concentrations.
International Journal of ObesityWeight change and blood coagulability and fibrinolysis in healthy obese women
58 Citations2001P Rissanen, Elina Vahtera +3 more
The maintenance of modest weight loss is associated with long-term benefits in PAI-1 and FVII in obese women and the change of serum insulin is related with the changes of PAi-1 activities, while fibrinogen is not affected by modest weight Loss.
Diabetes Obesity and MetabolismDecreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors
54 Citations2003Linda M. Samuelsson, Anders Gottsäter +1 more
Changes in the leucocyte derived inflammatory mediators tumour necrosis factor alpha (TNF‐α), interleukin 6 (IL‐6) and the isoprostane 8‐epi‐prostaglandin (PG) F2α during BMI lowering with orlistat (Xenical®, Roche) or placebo are evaluated.
The American Journal of CardiologyEffect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia
52 Citations2003Charles Lucas, Mark Boldrin +1 more
Weight loss in response to a reduced calorie diet in obese hypercholesterolemic patients was associated with a significant decrease in plasma LDL cholesterol levels, and the beneficial metabolic effects of weight loss were accentuated in Response to orlistat administration.
Journal of the American College of NutritionThe Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents
50 Citations2003Jianguo Zhi, Rema Moore +1 more
Administration of orlistat had no significant effect on the balance of six selected minerals in adolescent obese patients, and serum and urine electrolytes as well as urinary creatinine excretion were not affected byOrlistat treatment.
The Journal of Clinical PharmacologyThe Effect of Orlistat on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers
45 Citations1996Jianguo Zhi, Angela T. Melia +5 more
Orlistat administered at doses of 120 mg three times daily did not significantly alter the pharmacokinetics and pharmacodynamics of a single 30‐mg oral dose of warfarin in healthy volunteers.
Diabetic MedicineAcute effect of orlistat on post‐prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus
41 Citations2002Kathryn Choon Beng Tan, Annette W.K. Tso +3 more
It is postulate that orlistat, a gastrointestinal lipase inhibitor, may cause changes in post‐prandial lipoprotein metabolism by reducing dietary triglyceride absorption.
The American Journal of CardiologyUsefulness of Orlistat in the treatment of severe hypertriglyceridemia
34 Citations2002Anthony S. Wierzbicki, Tim Reynolds +1 more
Lovastatin ER is safe and effective for the treatment of adults with hypercholesterolemia, and may be associated with a lower risk of myalgia or myositis because of the lower peak plasma concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors associated with the extended-release delivery system.
PubMedChanges in lipoprotein(a) levels and hormonal correlations during a weight reduction program.
30 Citations2001Dimitrios N. Kiortsis, Themistoklis Tzotzas +5 more
A low-calorie diet associated with weight loss in obese subjects may have beneficial effects on serum lipoprotein (a) levels in patients with high pre-treatment Lp(a) concentrations, independent of the hormonal changes observed during weight loss.
PubMedThe effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-I and B, and lipoprotein(a).
28 Citations1993Erik Muls, Kitty P. Kempen +3 more
It is concluded that short-term substantial weight loss in normolipidemic obese women resulted in a lowering of Lp(a) only in individuals with pre-treatment Lp (a) levels above 30 mg/dl, and that apo E polymorphism did not affect Lp-a levels at baseline nor the changes in lipoprotein variables, including Lp-(a), during weight loss.
PubMedReduction of lipoprotein (a) by weight loss.
27 Citations1990Andreas Sönnichsen, Werner Richter +1 more
Weight reduction by a 4000 kJ protein enriched diet for four weeks led to a mean 19 percent reduction of Lp(a) serum levels in men and premenopausal women, implying that an intraindividual interdependence between Lp-a and body weight seems to be possible although an interindividual correlation can not be shown.
International Journal of ObesityEffects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents
25 Citations2001S Gallistl, KM Sudi +3 more
Energy restriction combined with physical activity improves the haemostatic risk profile in obese children and adolescents.
Journal of NutritionShort-Term Orlistat Treatment Does Not Affect Mineral Balance and Bone Turnover in Obese Men
21 Citations2001Daniel G. Pace, Steven Blotner +1 more
In obese men consuming a hypocaloric diet, the administration of orlistat had no significant effect on the balance of six selected minerals, and biomarkers of bone turnover, as well as serum and urine electrolytes, were not affected by Orlistat treatment.
Current Therapeutic ResearchEffects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial
21 Citations2002Giuseppe Derosa, Amedeo Mugellini +3 more
The combination treatment showed significantly greater reductions in serum TC and LDL-C levels, BMI, WCR, and BWL than with either orlistat or simvastatin alone, and small but significant differences in blood pressure were found with combination treatment.
Obesity SurgeryLipoprotein A Levels after Intestinal Bypass Operation for Morbid Obesity
17 Citations1997Lars Boman, Martin Ericson
Lowered Lp(a) levels are correlated to substantial weight loss following intestinal bypass surgery for obesity.
AtherosclerosisAdministration of orlistat in a patient with familial hyperchylomicronemia
14 Citations2002Themistoklis Tzotzas, Gerasimos E Krassas +1 more
PubMedOrlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
14 Citations2000Dragan Micić, T Ivković-Lazar +4 more
Orlistat in combination with diet provides increased weight loss than diet alone, improvements of serum lipids in subjects with hyperlipidemia and it has a good tolerability profile without systemic effects.
Endocrine PracticeCombination of Gemfibrozil and Orlistat for Treatment of Combined Hyperlipidemia With Predominant Hypertriglyceridemia
12 Citations2002Marsha C. Tolentino, Andrea Ferenczi +2 more
The combination of gemfibrozil and orlistat was extremely effective in reducing serum triglyceride levels in this patient with combined hyperlipidemia and predominant hypertriglyceridemia, whereas either one of these agents, when used alone, was ineffective.
PubMed[Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment].
6 Citations2001Mária Audikovszky, Gyula Pados +6 more
It is concluded that orlistat tends to have an antioxidant effect, along with the standardised values for HDL (PON/HDL), even compared to the control diet group.
PubMedOrlistat use in overweight women with mild hypercholesterolemia.
5 Citations2002C. Petrogiannopoulos, Sotirios G. Kalogeropoulos +4 more
Orlistat in combination with a low-energy diet seems to have a beneficial effect on body weight and lipid profile in overweight women with mild hypercholesterolemia.